| Product Name | Human Myosin-10 (MYH10) ELISA Kit |
|---|---|
| Description | Myh10 was abundantly expressed in mouse brain and testis. It was also expressed in heart, lung, liver, and kidney, but not in skeletal muscle or spleen.Actin-activated MgATPase activity was decreased in MYH10 with either an asn97-to-lysine substitution, which is homologous to the N93K mutation in MYH9 that causes May-Hegglin anomaly , or an arg709-to-cysteine substitution, which causes developmental defects in brain and heart when present in mouse Myh10. The ability of MYH10 heavy meromyosin to support the movement of actin filaments over an MYH10-coated surface was reduced in heavy meromyosin with the N97K mutation and eliminated with the R709C mutation. Kinetic analysis indicated that the R709C mutation resulted in extremely tight affinity between MYH10 heavy meromyosin and ADP, reducing the rate of ADP release. This assay has high sensitivity and excellent specificity for detection of Human MYH10. No significant cross-reactivity or interference between Human MYH10 and analogues was observed. |
| Synonyms | MGC134913, MGC134914, NMMHCB, cellular myosin heavy chain, type B type B|myosin heavy chain, nonmuscle type B|myosin, heavy polypeptide 10, non-muscle|near to the ATP binding region|nonmuscle myosin |
| Method | Sandwich ELISA |
| Detection Range | 0.156-10 ng/mL |
| Sensitivity | 0.055 ng/mL |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background | Myh10 was abundantly expressed in mouse brain and testis. It was also expressed in heart, lung, liver, and kidney, but not in skeletal muscle or spleen.Actin-activated MgATPase activity was decreased in MYH10 with either an asn97-to-lysine substitution, which is homologous to the N93K mutation in MYH9 that causes May-Hegglin anomaly , or an arg709-to-cysteine substitution, which causes developmental defects in brain and heart when present in mouse Myh10. The ability of MYH10 heavy meromyosin to support the movement of actin filaments over an MYH10-coated surface was reduced in heavy meromyosin with the N97K mutation and eliminated with the R709C mutation. Kinetic analysis indicated that the R709C mutation resulted in extremely tight affinity between MYH10 heavy meromyosin and ADP, reducing the rate of ADP release. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
